ERBB2 and breast cancer: One systematic review aimed to determine whether there was an increased risk of cardiotoxicity in breast cancer patients treated with dual HER-2 blockade (pertuzumab plus trastuzumab, or trastuzumab plus lapatanib) compared to monotherapy (lapatanib or trastuzumab or pertuzumab) [24].